Announcements
5 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Breast Cancer Research
We are delighted to share some highly cited papers on breast cancer research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues that we believe will be of interest to you.
“Breast Tumour Classification Using Ultrasound Elastography with Machine Learning: A Systematic Scoping Review”
by Ye-Jiao Mao, Hyo-Jung Lim, Ming Ni, Wai-Hin Yan, Duo Wai-Chi Wong and James Chung-Wai Cheung
Cancers 2022, 14(2), 367; https://doi.org/10.3390/cancers14020367
Available online: https://www.mdpi.com/2072-6694/14/2/367
“Exosomes as Emerging Drug Delivery and Diagnostic Modality for Breast Cancer: Recent Advances in Isolation and Application”
by Dulla Naveen Kumar, Aiswarya Chaudhuri, Farrukh Aqil, Deepa Dehari, Radha Munagala, Sanjay Singh, Ramesh C. Gupta and Ashish Kumar Agrawal
Cancers 2022, 14(6), 1435; https://doi.org/10.3390/cancers14061435
Available online: https://www.mdpi.com/2072-6694/14/6/1435
“Role of ctDNA in Breast Cancer”
by Marta Sant, Adrià Bernat-Peguera, Eudald Felip and Mireia Margelí
Cancers 2022, 14(2), 310; https://doi.org/10.3390/cancers14020310
Available online: https://www.mdpi.com/2072-6694/14/2/310
“Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021”
by Maroun Bou Zerdan, Tala Ghorayeb, Fares Saliba, Sabine Allam, Morgan Bou Zerdan, Marita Yaghi, Nadeem Bilani, Rola Jaafar and Zeina Nahleh
Cancers 2022, 14(5), 1253; https://doi.org/10.3390/cancers14051253
Available online: https://www.mdpi.com/2072-6694/14/5/1253
“HER2-Low Breast Cancer: Molecular Characteristics and Prognosis”
by Elisa Agostinetto, Mattia Rediti, Danai Fimereli, Véronique Debien, Martine Piccart, Philippe Aftimos, Christos Sotiriou and Evandro de Azambuja
Cancers 2021, 13(11), 2824; https://doi.org/10.3390/cancers13112824
Available online: https://www.mdpi.com/2072-6694/13/11/2824
“Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?”
by Emma E. Newton, Lauren E. Mueller, Scout M. Treadwell, Cindy A. Morris and Heather L. Machado
Cancers 2022, 14(3), 482; https://doi.org/10.3390/cancers14030482
Available online: https://www.mdpi.com/2072-6694/14/3/482
|
“Comprehensive Genomic Profiling for Metastatic Breast Cancer: Current Status and Future Perspectives” Edited by: Dr. Hiroshi Tada and Dr. Hiroko Masuda
|
“Single Cell RNA Sequencing in Breast Cancer” Edited by: Dr. Yu-Chih Chen |
|
“Molecular Mechanisms in Breast Cancer Therapy and Resistance” Edited by: Dr. Lei Duan
|
“BRCA-Associated Breast Cancer” Edited by: Dr. Matilde Pensabene, Dr. Carmine De Angelis and Prof. Dr. Matteo Lambertini
|
We hope this announcement will provide useful information for this field.
4 July 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Resistance Research
We are delighted to share some highly cited papers on cancer resistance research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you. The list of relevant papers can be seen below:
“Mechanisms of Resistance to KRASG12C Inhibitors”
by Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall and Colin Lindsay
Cancers 2021, 13(1), 151; https://doi.org/10.3390/cancers13010151
Available online: https://www.mdpi.com/2072-6694/13/1/151
“Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance”
by Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin and Panagiotis Papageorgis
Cancers 2021, 13(17), 4363; https://doi.org/10.3390/cancers13174363
Available online: https://www.mdpi.com/2072-6694/13/17/4363
“Mechanisms of Resistance to Conventional Therapies for Osteosarcoma”
by Louise Marchandet, Morgane Lallier, Céline Charrier, Marc Baud’huin, Benjamin Ory and François Lamoureux
Cancers 2021, 13(4), 683; https://doi.org/10.3390/cancers13040683
Available online: https://www.mdpi.com/2072-6694/13/4/683
“Immune Resistance in Lung Adenocarcinoma”
by Magda Spella and Georgios T. Stathopoulos
Cancers 2021, 13(3), 384; https://doi.org/10.3390/cancers13030384
Available online: https://www.mdpi.com/2072-6694/13/3/384
“Recent Insights into Therapy Resistance in Osteosarcoma”
by Zachary D. Prudowsky and Jason T. Yustein
Cancers 2021, 13(1), 83; https://doi.org/10.3390/cancers13010083
Available online: https://www.mdpi.com/2072-6694/13/1/83
“EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance”
by Mary Luz Uribe, Ilaria Marrocco and Yosef Yarden
Cancers 2021, 13(11), 2748; https://doi.org/10.3390/cancers13112748
Available online: https://www.mdpi.com/2072-6694/13/11/2748
Special Issues:
|
“The Role of Epithelial-Mesenchymal Transition in Therapies Resistance and Cancer Metastasis” Edited by: Dr. Pierre Savagner
|
“State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers” Edited by: Dr. Yan Li |
|
“Drug Resistance in Gastrointestinal Cancer” Edited by: Dr. Rosalba D’Alessandro and Dr. Carmelo Ferrai
|
“Triple Negative Breast Cancer Therapy Resistance and Metastasis” Edited by: Dr. Daniela Sousa
|
4 July 2023
Cancers Receives an Updated Impact Factor of 5.2
3 July 2023
MDPI Insights: The CEO's Letter #1 - Open Access and Impactful Research
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
The Future is Open, and MDPI is Leading the Way
I strongly believe in a future that embraces openness, where open source, open information, and open access (OA) take center stage. This belief that led me to join MDPI in 2020, and I am honored to have recently been appointed as Chief Executive Officer (CEO). In this capacity, and operating in close liaison with Dr. Lin and MDPI’s senior management, I shall work to build on Dr. Lin’s achievements of the past quarter-century. In this role, I will focus on communication initiatives to promote MDPI's remarkable work and continue to build our company as a trusted leader in OA publishing. For over two decades, MDPI has been at the forefront of reshaping the academic publishing landscape, with OA surpassing subscription-based publishing in 2020. This trajectory is deeply rooted in our history and reflects our unwavering commitment and vision for an open future.
1 Million Published Articles
2023 began with a remarkable achievement for MDPI, as we became the first OA publisher to reach the milestone of 1 million published articles. This represents 2.7 million unique authors who have trusted us with their work, or about a third of all researchers worldwide. As the world's most cited OA publisher, we are proud in sharing these significant milestones.
Our mission remains unchanged: to make science open and accessible to all. We understand the importance of knowledge access, empowering researchers to stay at the forefront of a rapidly changing world. Our diverse range of journals covers a wide spectrum of disciplines, offering cutting-edge insights, trusted tools, and crucial knowledge to address global challenges.
Liberating Science
As the world’s leading OA publisher, MDPI is actively liberating science. We are committed to eliminating the frustrations researchers and the general public face when accessing information, ensuring it is not locked behind paywalls. We firmly believe that everyone has a right to information, and our commitment to open access publishing drives our work.
In this inaugural edition of Insights: The CEO's Letter, I draw inspiration from the upcoming 20th anniversary of the Berlin Declaration on Open Access. Its stated mission reminds us that true impact is achieved when knowledge is widely and readily available to society:
"Our mission of disseminating knowledge is only half complete if the information is not made widely and readily available to society”
Impactful Research
MDPI Publishes Impactful Research: Recognized by Leading Indexing Databases
MDPI journals are indexed in every single top database in the world.
As of June 2023, we have 214 journals indexed within Web of Science, 223 indexed within Scopus, 87 indexed within PubMed and PMC, and 17 indexed within MEDLINE, and these numbers increase every month. We constantly strive to expand the coverage of our journals within leading multi-disciplinary and scope-specific databases, resulting in an incredibly broad range of journals that are indexed within a variety of databases. MDPI has active relationships with approximately 65 well-known databases around the world, and we continue to expand our portfolio every year so that your work can be found, cited, and referenced with ease.
Continued Growth of MDPI Journals
The 2022 Scopus and Web of Science journal citation metrics were officially released in June, and I am pleased to report that 31 MDPI journals received their first CiteScore, taking the total number of journals with a CiteScore to 216. The number of MDPI journals receiving an Impact Factor (IF) also continues to grow with 111 receiving their first, by being covered in the ESCI, bringing our total number of journals with an IF to 208 of which 41 journals received an IF above 4.0. Looking at 2022 CiteScores in the Scopus database, 80% of MDPI journals have a score that ranks them in Q1 or Q2 in at least one subject category.
Publishing impactful science would not be possible without all of our authors, editors and reviewers. Thank you for your contribution and continued support! Together we share the latest scientific insights faster and ensure that your work is accessible to all.
Read more
Inside MDPI
Preprints.org: Clarivate adds the Preprint Citation Index to the Web of Science
At MDPI, we are dedicated to driving the advancement of science. Through our initiative, Preprints.org, researchers can publish their work and gain valuable feedback from the broader research community, ensuring rapid progress in their respective fields. This is particularly crucial during times of health and climate challenges, where timely dissemination of findings is essential.
Increased Visibility for Preprints
I am pleased to share that Clarivate recognizes the significance of preprints and has taken a crucial step to enhance their visibility. Clarivate has added the Preprint Citation Index to the Web of Science, encompassing preprints published not only on Preprints.org but also on other reputable repositories.
Looking ahead, the future of preprints appears promising, bolstered by the recent indexing announcement from the Web of Science. As a result, preprints will receive increased visibility, serving as a valuable resource for staying informed about the latest research developments.
Read more
What are Preprints?
The Pros and Cons of Preprints
Preprints and COVID-19
Preprints—The Future of Open Access Publishing?
Coming Together for Science
The First International Conference on Antioxidants: Sources, Methods, Health Benefits and Industrial Applications
In this edition of ‘Coming Together for Science,’ I am pleased to highlight the First International Conference on Antioxidants organized by our conference team in the beautiful city of Barcelona, Spain. The conference attracted over 130 attendees, who engaged in 42 talks, and 89 poster presentations spread across several sessions.
Working Together
Under the leadership of Prof. Dr. Alessandra Napolitano (Department of Chemical Sciences, University of Naples ‘Federico II’, Naples, Italy) and Prof. Dr. Rosa M. Lamuela Raventos (Department of Nutrition, Food Sciences and Gastronomy, University of Barcelona, Spain) as chairs, and supported by the committee members, 10 invited keynote speakers, poster presenters, and all the attendees, this dedicated group of academics came together to discuss the natural sources, methodologies, health benefits, and industrial applications of antioxidants.
Especially noteworthy is the positive feedback received from attendees, with 94% rating the overall organization of the conference as good or excellent. I particularly love the picture above, capturing the gathering of some of the participants. You can browse through more photos in the event gallery located here.
Managing Events With Sciforum
If you are considering hosting your own academic event, I highly recommend checking out Sciforum, MDPI's event management platform. Sciforum simplifies the entire process, making it easy to host your own event by allowing you to focus on what really matters: Science!
Read more
Closing Thoughts
Stefan Tochev, Dr. Shu-Kun Lin, Dr. Eric O. Freed, Peter Roth, Wynne Wang, Allison Yang
Viruses and Editorial Quality: Acknowledging the Dedication of our Viruses Journal Team
During a June meeting with Dr. Eric O. Freed, the founding and current Editor-in-Chief of our journal Viruses, I was reminded of the exceptional dedication of our editorial board. Meeting with Eric is a pleasure, as he has a strong commitment and clear vision for the journal. Over the course of two days, we gained a deep understanding of the journal’s expectations and focus on strategic growth, editorial board representation, and engagement.
I am pleased to share that Viruses holds a CiteScore of 7.1 (an increase of 7.57% versus the 2021 metric) and an Impact Factor of 4.7. You can view the journal statistics here. Viruses publishes highly cited papers, and is indexed in renowned databases such as Scopus, SCIE (Web of Science), PubMed, and others, and maintains affiliations with prestigious societies. Moreover, the Viruses team has recently announced an exciting upcoming event titled ‘Viruses 2024 – A World of Viruses,’ scheduled to take place in Barcelona, Spain, from 14–16 February 2024.
Testimonials
If you notice my enthusiasm regarding our editorial service, it’s because the surveys and testimonials we receive speak volumes about the experiences of our authors, reviewers, and guest editors who collaborate with MDPI. The purpose of these letters is to highlight the exceptional work that we do and the experiences we create for the scholars – thus, let me end with this testimonial from an author:
“It was a great pleasure to publish in Viruses Special Issue [Emerging Viruses in Aquaculture]. The submission process was easy. Guest editors were very helpful and provided all the guidance and support as needed. The handling of the manuscript by the Editorial Team was very fast, efficient, and professional. The reviewer’s comments were insightful, and the publication processes were remarkably rapid.”
– Ms. Magdalena Stachnik, Państwowy Instytut Weterynaryjny | PIWet
Article in Viruses: Emerging Viral Pathogens in Sturgeon Aquaculture in Poland: Focus on Herpesviruses and Mimivirus Detection
Chief Executive Officer
MDPI AG
29 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Epidemiology and Prevention
We are delighted to share some highly cited papers on cancer epidemiology and prevention that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission.
“Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies”
by Md. Sanower Hossain, Hidayah Karuniawati, Ammar Abdulrahman Jairoun, Zannat Urbi, Der Jiun Ooi, Akbar John, Ya Chee Lim, K. M. Kaderi Kibria, A. K. M. Mohiuddin, Long Chiau Ming et al.
Cancers 2022, 14(7), 1732; https://doi.org/10.3390/cancers14071732
Available online: https://www.mdpi.com/2072-6694/14/7/1732
“A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis”
by Tomasz Sawicki, Monika Ruszkowska, Anna Danielewicz, Ewa Niedźwiedzka, Tomasz Arłukowicz and Katarzyna E. Przybyłowicz
Cancers 2021, 13(9), 2025; https://doi.org/10.3390/cancers13092025
Available online: https://www.mdpi.com/2072-6694/13/9/2025
“Epidemiology of Glioblastoma Multiforme–Literature Review”
by Szymon Grochans, Anna Maria Cybulska, Donata Simińska, Jan Korbecki, Klaudyna Kojder, Dariusz Chlubek and Irena Baranowska-Bosiacka
Cancers 2022, 14(10), 2412; https://doi.org/10.3390/cancers14102412
Available online: https://www.mdpi.com/2072-6694/14/10/2412
“Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review”
by Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, Jacek Baj, Robert Sitarz and Andrzej Stanisławek
Cancers 2021, 13(17), 4287; https://doi.org/10.3390/cancers13174287
Available online: https://www.mdpi.com/2072-6694/13/17/4287
“Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries”
by Junjie Huang, Anastasios Koulaouzidis, Wojciech Marlicz, Veeleah Lok, Cedric Chu, Chun Ho Ngai, Lin Zhang, Ping Chen, Shanjuan Wang, Jinqiu Yuan et al.
Cancers 2021, 13(1), 141; https://doi.org/10.3390/cancers13010141
Available online: https://www.mdpi.com/2072-6694/13/1/141
|
“Feature Paper in Section “Cancer Epidemiology and Prevention” in 2022–2023“ |
“How COVID-19 Affects Cancer Patients“ |
|
“Colorectal Cancer: Epidemiology and Prevention“ |
“Inherited Breast Cancer Risk: BRCA Mutations and Beyond“ |
We hope this announcement will provide useful information for this field.
29 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Cancer Therapy
We are delighted to share some highly cited papers on cancer therapy research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.
"STING Agonists as Cancer Therapeutics"
by Afsaneh Amouzegar, Manoj Chelvanambi, Jessica N. Filderman, Walter J. Storkus and Jason J. Luke
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695
"MMP9: A Tough Target for Targeted Therapy for Cancer"
by Katarzyna Augoff, Anita Hryniewicz-Jankowska, Renata Tabola and Kamilla Stach
Cancers 2022, 14(7), 1847; https://doi.org/10.3390/cancers14071847
Available online: https://www.mdpi.com/2072-6694/14/7/1847
"Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives"
by Nora Berois, Alvaro Pittini and Eduardo Osinaga
Cancers 2022, 14(3), 645; https://doi.org/10.3390/cancers14030645
Available online: https://www.mdpi.com/2072-6694/14/3/645
"The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment"
by Keiko Taguchi and Masayuki Yamamoto
Cancers 2021, 13(1), 46; https://doi.org/10.3390/cancers13010046
Available online: https://www.mdpi.com/2072-6694/13/1/46
"Photodynamic Therapy: A Compendium of Latest Reviews"
by José Francisco Algorri, Mario Ochoa, Pablo Roldán-Varona, Luís Rodríguez-Cobo and José Miguel López-Higuera
Cancers 2021, 13(17), 4447; https://doi.org/10.3390/cancers13174447
Available online: https://www.mdpi.com/2072-6694/13/17/4447
"Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives"
by Cristina Birzu, Pim French, Mario Caccese, Giulia Cerretti, Ahmed Idbaih, Vittorina Zagonel and Giuseppe Lombardi
Cancers 2021, 13(1), 47; https://doi.org/10.3390/cancers13010047
Available online: https://www.mdpi.com/2072-6694/13/1/47
"Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives"
by Shirin Hafezi and Mohamed Rahmani
Cancers 2021, 13(6), 1292; https://doi.org/10.3390/cancers13061292
Available online: https://www.mdpi.com/2072-6694/13/6/1292
|
“Feature Review for Cancer Therapy”
|
“Novel Therapeutic Strategies in Salivary Gland Tumor” |
|
“State-of-the-Art Mechanisms of Drug Resistance to Targeted Therapy in Cancers” |
“New Strategies in Diagnosis and Treatments for Brain Tumors (Volume II)” |
We hope this announcement will provide useful information for this field.
29 June 2023
Meet Us at the ESMO Congress 2023, 20–24 October 2023, Madrid, Spain
28 June 2023
2022 Impact Factors for MDPI Journals
The 2022 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:
We are thrilled to announce that 90% of our ranked MDPI journals, specifically 86 out of 96 (captured in the table below), are performing above average in Q1 or Q2. This year, Clarivate has expanded its Impact Factor (IF) awards to include journals in the Emerging Sources Citation Index (ESCI) and the Arts and Humanities Citation Index (AHCI), providing greater transparency for the full set of journals indexed in the Web of Science Core Collection. As a result, 111 of MDPI journals have received their first IF in 2023, with 37 journals surpassing an IF of 3.0. In total, 208 MDPI journals have been honored with an IF.
Clarivate explains that by "expanding the coverage but holding to highly selective standards, the [Impact Factor] is now a reliable indicator of trustworthiness, as well as a measure of scholarly impact, at the journal level."
Please visit our blog post where we discuss the release of the latest citation metrics with our Indexing Manager, Dr. Constanze Schelhorn, to find out what's different this time around and how to make use of different metrics available.
| Journal | Impact Factor | Rank Quartile | Category |
| Vaccines | 7.8 | Q1 | Immunology |
| Medicine, Research & Experimental | |||
| Antioxidants | 7.0 | Q1 | Food Science & Technology |
| Biochemistry & Molecular Biology | |||
| Chemistry, Medicinal | |||
| Cells | 6.0 | Q2 | Cell Biology |
| Nutrients | 5.9 | Q1 | Nutrition & Dietetics |
| International Journal of Molecular Sciences | 5.6 | Q1 | Biochemistry & Molecular Biology |
| Q2 | Chemistry, Multidisciplinary | ||
| Journal of Theoretical and Applied Electronic Commerce Research | 5.6 | Q2 | Business |
| Biomolecules | 5.5 | Q1 | Biochemistry & Molecular Biology |
| Biosensors | 5.4 | Q1 | Chemistry, Analytical |
| Instruments & Instrumentation | |||
| Q2 | Nanoscience & Nanotechnology | ||
| Fractal and Fractional | 5.4 | Q1 | Mathematics, Interdisciplinary Applications |
| Marine Drugs | 5.4 | Q1 | Chemistry, Medicinal |
| Pharmacology & Pharmacy | |||
| Pharmaceutics | 5.4 | Q1 | Pharmacology & Pharmacy |
| Nanomaterials | 5.3 | Q1 | Physics, Applied |
| Q2 | Chemistry, Multidisciplinary | ||
| Materials Science, Multidisciplinary | |||
| Nanoscience & Nanotechnology | |||
| Cancers | 5.2 | Q2 | Oncology |
| Foods | 5.2 | Q1 | Food Science & Technology |
| Polymers | 5.0 | Q1 | Polymer Science |
| Remote Sensing | 5.0 | Q1 | Geosciences, Multidisciplinary |
| Q2 | Remote Sensing | ||
| Imaging Science & Photographic Technology | |||
| Environmental Sciences | |||
| Antibiotics | 4.8 | Q1 | Pharmacology & Pharmacy |
| Q2 | Infectious Diseases | ||
| Drones | 4.8 | Q2 | Remote Sensing |
| Journal of Functional Biomaterials | 4.8 | Q2 | Engineering, Biomedical |
| Materials Science, Biomaterials | |||
| Biomedicines | 4.7 | Q1 | Pharmacology & Pharmacy |
| Q2 | Biochemistry & Molecular Biology | ||
| Medicine, Research & Experimental | |||
| Journal of Fungi | 4.7 | Q2 | Mycology |
| Microbiology | |||
| Viruses | 4.7 | Q2 | Virology |
| Bioengineering | 4.6 | Q2 | Engineering, Biomedical |
| Gels | 4.6 | Q1 | Polymer Science |
| Molecules | 4.6 | Q2 | Chemistry, Multidisciplinary |
| Biochemistry & Molecular Biology | |||
| Pharmaceuticals | 4.6 | Q2 | Pharmacology & Pharmacy |
| Chemistry, Medicinal | |||
| Toxics | 4.6 | Q1 | Toxicology |
| Q2 | Environmental Sciences | ||
| Biomimetics | 4.5 | Q1 | Engineering, Multidisciplinary |
| Q2 | Materials Science, Biomaterials | ||
| Microorganisms | 4.5 | Q2 | Microbiology |
| Plants | 4.5 | Q1 | Plant Sciences |
| Biology | 4.2 | Q2 | Biology |
| Chemosensors | 4.2 | Q2 | Instruments & Instrumentation |
| Chemistry, Analytical | |||
| Electrochemistry | |||
| Membranes | 4.2 | Q2 | Engineering, Chemical |
| Materials Science, Multidisciplinary | |||
| Chemistry, Physical | |||
| Polymer Science | |||
| Toxins | 4.2 | Q1 | Toxicology |
| Q2 | Food Science & Technology | ||
| Metabolites | 4.2 | Q2 | Biochemistry & Molecular Biology |
| Batteries | 4.0 | Q2 | Electrochemistry |
| Materials Science, Multidisciplinary | |||
| Q3 | Energy & Fuels | ||
| Catalysts | 3.9 | Q2 | Chemistry, Physical |
| Journal of Clinical Medicine | 3.9 | Q2 | Medicine, General & Internal |
| Land | 3.9 | Q2 | Environmental Studies |
| Sensors | 3.9 | Q2 | Instruments & Instrumentation |
| Chemistry, Analytical | |||
| Engineering, Electrical & Electronic | |||
| Sustainability | 3.9 | Q2 | Environmental Sciences (SCIE) |
| Environmental Studies (SSCI) | |||
| Q3 | Green & Sustainable Science & Technology (SCIE) | ||
| Green & Sustainable Science & Technology (SSCI) | |||
| Buildings | 3.8 | Q2 | Construction & Building Technology |
| Engineering, Civil | |||
| Agronomy | 3.7 | Q1 | Agronomy |
| Q2 | Plant Sciences | ||
| Fermentation | 3.7 | Q2 | Biotechnology & Applied Microbiology |
| Pathogens | 3.7 | Q2 | Microbiology |
| Agriculture | 3.6 | Q1 | Agronomy |
| Diagnostics | 3.6 | Q2 | Medicine, General & Internal |
| Genes | 3.5 | Q2 | Genetics & Heredity |
| Journal of Intelligence | 3.5 | Q2 | Psychology, Multidisciplinary |
| Lubricants | 3.5 | Q2 | Engineering, Mechanical |
| Processes | 3.5 | Q2 | Engineering, Chemical |
| Coatings | 3.4 | Q2 | Materials Science, Coatings & Films |
| Physics, Applied | |||
| Q3 | Materials Science, Multidisciplinary | ||
| ISPRS International Journal of Geo-Information | 3.4 | Q2 | Geography, Physical |
| Q3 | Computer Science, Information Systems | ||
| Remote Sensing | |||
| Materials | 3.4 | Q2 | Metallurgy & Metallurgical Engineering |
| Physics, Applied | |||
| Physics, Condensed Matter | |||
| Q3 | Materials Science, Multidisciplinary | ||
| Chemistry, Physical | |||
| Micromachines | 3.4 | Q2 | Instruments & Instrumentation |
| Physics, Applied | |||
| Chemistry, Analytical | |||
| Q3 | Nanoscience & Nanotechnology | ||
| Water | 3.4 | Q2 | Water Resources |
| Environmental Sciences | |||
| Brain Sciences | 3.3 | Q3 | Neurosciences |
| Energies | 3.2 | Q3 | Energy & Fuels |
| Fire | 3.2 | Q1 | Forestry |
| Q2 | Ecology | ||
| Life | 3.2 | Q2 | Biology |
| Current Issues in Molecular Biology | 3.1 | Q3 | Biochemistry & Molecular Biology |
| Horticulturae | 3.1 | Q1 | Horticulture |
| Animals | 3.0 | Q1 | Agriculture, Dairy & Animal Science |
| Veterinary Sciences | |||
| Insects | 3.0 | Q1 | Entomology |
| Atmosphere | 2.9 | Q3 | Meteorology & Atmospheric Sciences |
| Environmental Sciences | |||
| Electronics | 2.9 | Q2 | Engineering, Electrical & Electronic |
| Physics, Applied | |||
| Q3 | Computer Science, Information Systems | ||
| Forests | 2.9 | Q1 | Forestry |
| Inorganics | 2.9 | Q2 | Chemistry, Inorganic & Nuclear |
| Journal of Marine Science and Engineering | 2.9 | Q1 | Engineering, Marine |
| Q2 | Oceanography | ||
| Engineering, Ocean | |||
| Metals | 2.9 | Q2 | Metallurgy & Metallurgical Engineering |
| Q3 | Materials Science, Multidisciplinary | ||
| Tropical Medicine and Infectious Disease | 2.9 | Q2 | Tropical Medicine |
| Parasitology | |||
| Q3 | Infectious Diseases | ||
| Universe | 2.9 | Q2 | Astronomy & Astrophysics |
| Physics, Particles & Fields | |||
| Healthcare | 2.8 | Q2 | Health Policy & Services (SSCI) |
| Q3 | Health Care Sciences & Services (SCIE) | ||
| Applied Sciences | 2.7 | Q2 | Engineering, Multidisciplinary |
| Physics, Applied | |||
| Q3 | Chemistry, Multidisciplinary | ||
| Materials Science, Multidisciplinary | |||
| Crystals | 2.7 | Q2 | Crystallography |
| Q3 | Materials Science, Multidisciplinary | ||
| Entropy | 2.7 | Q2 | Physics, Multidisciplinary |
| Magnetochemistry | 2.7 | Q2 | Chemistry, Inorganic & Nuclear |
| Q3 | Chemistry, Physical | ||
| Materials Science, Multidisciplinary | |||
| Symmetry | 2.7 | Q2 | Multidisciplinary Sciences |
| Actuators | 2.6 | Q2 | Instruments & Instrumentation |
| Engineering, Mechanical | |||
| Aerospace | 2.6 | Q1 | Engineering, Aerospace |
| Behavioral Sciences | 2.6 | Q2 | Psychology, Multidisciplinary |
| Current Oncology | 2.6 | Q3 | Oncology |
| Machines | 2.6 | Q2 | Engineering, Mechanical |
| Q3 | Engineering, Electrical & Electronic | ||
| Medicina | 2.6 | Q3 | Medicine, General & Internal |
| Separations | 2.6 | Q3 | Chemistry, Analytical |
| Minerals | 2.5 | Q2 | Mining & Mineral Processing |
| Mineralogy | |||
| Geochemistry & Geophysics | |||
| Children | 2.4 | Q2 | Pediatrics |
| Diversity | 2.4 | Q2 | Biodiversity Conservation |
| Q3 | Ecology | ||
| Journal of Cardiovascular Development and Disease | 2.4 | Q3 | Cardiac & Cardiovascular Systems |
| Mathematics | 2.4 | Q1 | Mathematics |
| Photonics | 2.4 | Q3 | Optics |
| Veterinary Sciences | 2.4 | Q1 | Veterinary Sciences |
| Fishes | 2.3 | Q2 | Marine & Freshwater Biology |
| Fisheries | |||
| Axioms | 2.0 | Q2 | Mathematics, Applied |
| Systems | 1.9 | Q2 | Social Sciences, Interdisciplinary |
| Tomography | 1.9 | Q3 | Radiology, Nuclear Medicine & Medical Imaging |
Note: The Journal of Personalized Medicine's Impact Factor was omitted in the original release and will be assigned separately. Please find the data on the journal webpage in due course.
Source: 2022 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2023)
25 June 2023
Cancers | Highly Cited Papers and Hot Topic Special Issues on Clinical Cancer Research
We are delighted to share some highly cited papers on clinical cancer research that were published in the journal Cancers (ISSN: 2072-6694) in 2021-2022. In addition, some Special Issues on this topic are open for submission.
“Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?”
by Saikat Mitra, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, Kuldeep Dhama, M. Yasmin Begum, Afaf Aldahish et al.
Cancers 2022, 14(3), 759; https://doi.org/10.3390/cancers14030759
Available online: https://www.mdpi.com/2072-6694/14/3/759
“Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives”
by Fidan Seker-Polat, Nareg Pinarbasi Degirmenci, Ihsan Solaroglu and Tugba Bagci-Onder
Cancers 2022, 14(2), 443; https://doi.org/10.3390/cancers14020443
Available online: https://www.mdpi.com/2072-6694/14/2/443
“Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer”
by Kamya Sankar, Alex K. Bryant, Garth W. Strohbehn, Lili Zhao, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath and Michael D. Green
Cancers 2022, 14(3), 614; https://doi.org/10.3390/cancers14030614
Available online: https://www.mdpi.com/2072-6694/14/3/614
“Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic”
by Ana Isabel Fraguas-Sánchez, Irene Lozza and Ana Isabel Torres-Suárez
Cancers 2022, 14(5), 1198; https://doi.org/10.3390/cancers14051198
Available online: https://www.mdpi.com/2072-6694/14/5/1198
“New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines”
by Angela Santoro, Giuseppe Angelico, Antonio Travaglino, Frediano Inzani, Damiano Arciuolo, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Vincenzo Fiorentino, Antonio Raffone et al.
Cancers 2021, 13(11), 2623; https://doi.org/10.3390/cancers13112623
Available online: https://www.mdpi.com/2072-6694/13/11/2623
“The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications”
by John Charles Rotondo, Chiara Mazziotta, Carmen Lanzillotti, Chiara Stefani, Giada Badiale, Giulia Campione, Fernanda Martini and Mauro Tognon
Cancers 2022, 14(5), 1116; https://doi.org/10.3390/cancers14051116
Available online: https://www.mdpi.com/2072-6694/14/5/1116
|
“Clinical Trials for Pancreatic Cancer Diagnosis and Treatment” Edited by: Dr. Takuji Okusaka
|
“Advances in Clinical Trials of Hematological Malignancies” Edited by: Dr. Lajos Gergely |
|
“Steps towards the Clinics in Spatially Fractionated Radiation Therapy” Edited by: Dr. Stefan Bartzsch
|
“Strategies for Clinical Cancer Chemoprevention: From Bench to Bedside” Edited by: Dr. Nagi B. Kumar
|
We hope this announcement will provide useful information for this field.
21 June 2023
Cancers Receives an Increased CiteScore of 7.4
